Table 3 Phenotyping of naive CD4⁺ T-cells from healthy donors (HD) and patients (Pat) with/without MSCs

TEMRA

CD45RA⁺CD27⁻

%

Absolute count

0.5 ± 0.3 (0.6; 0.2–0.8)^a

150 ± 90

(180; 60–240)

1.8 ± 1.3 (1.8; 0.5–3.0)

540 ± 390

(540; 150–900)

2.0 ± 2.7 (0.7; 0.4–6.0)

600 ± 810

(210; 120–1800)

2.9 ± 4.0 (1.2; 0.3–8.9)

870 ± 1200

(360; 90–2670)

Naive

CD45RA⁺CD27⁺

%

Absolute count

32.2 ± 7.8 (30.6; 25.8–41.9)

9660 ± 2340

(9180; 7740–12,570)

26.0 ± 3.8 (25.6; 21.8–31.1)

7800 ± 1140

(7680; 6540–9330)

35.8 ± 22.8 (25.3; 22.8–69.9)

10,740 ± 6840

(7590; 6840–20,970)

17.3 ± 6.5 (15.0; 12.4–26.9)

5190 ± 1950

(4500; 3720–8070)

Memory

CD45RA⁺CD27⁺

%

Absolute count

65.5 ± 6.6 (66.6; 57.1–71.9)

19,650 ± 1980

(19,980; 17,130–21,570)

52.1 ± 13.4 (51.5; 39.3–66.0)

15,630 ± 4020

(15,450; 11,790–19,800)

59.3 ± 27.5 (72.4; 18.1–74.3)

17,790 ± 8250

(21,720; 5430–22,290)

60.5 ± 22.6 (69.8; 27.1–75.3)

18,150 ± 6780

(20,940; 8130–22,590)

Effector

CD45RA⁻CD27⁻

%

Absolute count

1.8 ± 1.6 (1.4; 0.5–4.0)

540 ± 480

(420; 150–1200)

20.3 ± 9.7 (21.8; 8.2–29.3)^a

6090 ± 2910

(6540; 2460–8790)

2.9 ± 2.2 (2.6; 0.6–5.9)

870 ± 660

(780; 180–1770)

19.3 ± 12.2 (14.9; 10.5–37.1)^b

5790 ± 3660

(4470; 3150–11,130)